MRK vs TTD: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and The Trade Desk, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
VS
The Trade Desk, Inc. · Technology
$22.76
+488.8% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
TTD has more upside to fair value
(+488.8%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
TTD |
| Current Price |
$121.42 |
$22.76 |
| Fair Value Estimate |
$118.00 |
$134.00 |
| Upside to Fair Value |
-2.9%
|
+488.8%
|
| Market Cap |
$300.2B |
$10.8B |
| Forward P/E |
14.0x
|
24.6x
|
| EV / EBITDA |
11.8x
|
—
|
| Price / Sales |
4.1x
|
3.7x
|
| Price / FCF |
21.4x
|
13.8x
|
| Revenue Growth YoY |
+1.3%
|
+14.5%
|
| Gross Margin |
81.5%
|
78.6%
|
| Operating Margin |
41.2%
|
20.3%
|
| Return on Equity |
34.7%
|
16.9%
|
| Dividend Yield |
3.1% |
— |
| FCF Yield |
4.7%
|
7.3%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
The Trade Desk is the largest independent demand-side platform for programmatic advertising with 78.6% gross margins. After recent sell-off, stock trades at 3.2x forward P/S vs historical higher multiples, offering upside if growth stabilizes at 15%+. A-tier business at cheap valuation.[1]
Accumulation Zones
| Metric |
MRK |
TTD |
| Zone Low |
$88.00 |
$100.00 |
| Zone High |
$100.00 |
$114.00 |
| In Buy Zone? |
No
|
Yes
|